Biotechs working in early stage drug development are tapping into new sources of funding. Family offices, foundations, impact investors and venture accelerators are all playing a role in bringing new funding to these companies in order to accelerate the drug development process. Panelists will address such issues as how raising capital from these sources differs from traditional capital (e.g. Biopharma, VCs or Angels); what these non-traditional investors want for their money, how they collaborate, and how the process differs. Hear from active players about what they look for and how they've moved the ball down the field toward their investing goals. Blended ROI, social-impact as an economic driver, direct investments, and other trends.